Authors
Nicole Green, Daniel H Leung
Published in
Clinics in liver disease. Volume 30. Issue 4. Pages 863-882. Epub Sep 08, 2026.
Abstract
Cystic Fibrosis-associated Hepatobiliary involvement (CFHBI) refers to a wide range of liver and biliary-related clinical and/or biochemical abnormalities that impact people with cystic fibrosis. Advanced cystic fibrosis liver disease (aCFLD) describes individuals with advanced fibrosis or cirrhosis and/or portal hypertension. The current review discusses both CFHBI and aCFLD in terms of pathogenesis; clinical, imaging and biochemical manifestations; screening, monitoring, and management recommendations; and the impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy.
PMID:
42946521
Bibliographic data and abstract were imported from PubMed on 28 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0